US2017189485A1PendingUtilityA1

Modulation of estrogen receptor-related receptor gamma (err gamma) and uses therefor

Assignee: SALK INST FOR BIOLOGICAL STUDIPriority: Mar 1, 2011Filed: Jan 17, 2017Published: Jul 6, 2017
Est. expiryMar 1, 2031(~4.6 yrs left)· nominal 20-yr term from priority
A61P 9/00A61P 25/00A61K 48/005A61K 48/0066A61K 38/1796A61P 21/00A61K 48/00A61K 38/177A61P 13/12A61K 31/655A61K 31/381A61K 48/0058A61K 31/166
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERRγ activity to the subject. Such agents can include one or more ERRγ agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of increasing mitochondrial activity, comprising:
 administering a therapeutically effective amount of one or more agents that increases ERRγ activity to a mammal needing increased mitochondrial activity; and   not exercising the mammal.   
     
     
         2 . The method of  claim 1 , wherein the method further comprises:
 selecting a mammal in need of increased mitochondrial activity or a mammal at risk for developing a disorder that can benefit from increased mitochondrial activity.   
     
     
         3 . The method of  claim 1 , wherein increased mitochondrial activity is needed in the mammal's muscle. 
     
     
         4 . The method of  claim 1 , wherein the mammal has or is at risk for muscle atrophy, muscle wasting, sarcopenia, hearing loss, or mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episode syndrome (MELAS). 
     
     
         5 . The method of  claim 1 , wherein the one or more agents that increases ERRγ activity comprises:
 a nucleic acid molecule encoding ERRγ; 
 one or more ERRγ agonists; 
 an ERRγ protein; or 
 combinations thereof.

Join the waitlist — get patent alerts

Track US2017189485A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.